(Q37938086)

25 August 2017

1 reference

title

Nutrition in phenylketonuria (English)

1 reference

25 August 2017

1 reference

A MacDonald

1

1 reference

25 August 2017

J C Rocha

series ordinal

2

1 reference

25 August 2017

M van Rijn

series ordinal

3

1 reference

25 August 2017

F Feillet

series ordinal

4

1 reference

25 August 2017

2 September 2011

1 reference

Molecular Genetics and Metabolism

25 August 2017

1 reference

25 August 2017

104 Suppl

1 reference

25 August 2017

S10-8

1 reference

Molecular and integrative physiology of intestinal peptide transport

25 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Whole-body nitrogen and splanchnic amino acid metabolism differ in rats fed mixed diets containing casein or its corresponding amino acid mixture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Peripheral and splanchnic metabolism of dietary nitrogen are differently affected by the protein source in humans as assessed by compartmental modeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

INCAP studies of energy, amino acids, and protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Protein and amino acid requirements and the composition of complementary foods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Effect of simultaneous ingestion of L-amino acids and whole protein on plasma amino acid and urea nitrogen concentrations in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Plasma amino acid response to ingestion of L-amino acids and whole protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Comparison of growth performance and nutrient retention of weaner pigs given diets based on casein, free amino acids or conventional proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Nutritional management of PKU with glycomacropeptide from cheese whey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Breakfast with glycomacropeptide compared with amino acids suppresses plasma ghrelin levels in individuals with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Large neutral amino acids in the treatment of PKU: from theory to practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Recommendations on the dietary management of phenylketonuria. Report of Medical Research Council Working Party on Phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Is phenylalanine requirement in infants and children related to protein intake?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Administration of protein substitute and quality of control in phenylketonuria: a randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Protein substitute dosage in PKU: how much do young patients need?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Dependence of the utilization of a phenylalanine-free amino acid mixture on different amounts of single dose ingested. A case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Utilisation of amino acid mixtures in adolescents with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Aromatic amino acid requirements in healthy human subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Tyrosine requirements in children with classical PKU determined by indicator amino acid oxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Phenylketonuria: tyrosine supplementation in phenylalanine-restricted diets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Twenty-four-hour L-[1-(13)C]tyrosine and L-[3,3-(2)H2]phenylalanine oral tracer studies at generous, intermediate, and low phenylalanine intakes to estimate aromatic amino acid requirements in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Twenty-four-hour intravenous and oral tracer studies with L-[1-13C]phenylalanine and L-[3,3-2H2]tyrosine at a tyrosine-free, generous phenylalanine intake in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Different approaches to define individual amino acid requirements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Phenylalanine requirement in children with classical PKU determined by indicator amino acid oxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Nutrient intake of treated infants with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Influence of phenylalanine intake on phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Phenylalanine intakes of 1- to 6-year-old children with phenylketonuria undergoing therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Six-year follow up of phenylalanine intakes and plasma phenylalanine concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

BH(4) therapy impacts the nutrition status and intake in children with phenylketonuria: 2-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Three-year audit of the hyperphenylalaninaemia/phenylketonuria spectrum in Victoria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Phenylalanine tolerance can already reliably be assessed at the age of 2 years in patients with PKU.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Reassessment of phenylalanine tolerance in adults with phenylketonuria is needed as body mass changes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Adult patients with well-controlled phenylketonuria tolerate incidental additional intake of phenylalanine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Factors affecting the variation in plasma phenylalanine in patients with phenylketonuria on diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Malnutrition with early treatment of phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Dietary management practices in phenylketonuria across European centres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Blood phenylalanine control in phenylketonuria: a survey of 10 European centres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Does maternal knowledge and parent education affect blood phenylalanine control in phenylketonuria?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

A survey of natural protein intake in Dutch phenylketonuria patients: insight into estimation or measurement of dietary intake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

The development of nonweighed pilot methods for estimating phenylalanine exchanges in non-phenylketonuria volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Growth and skeletal maturation in children with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Impaired prenatal and postnatal growth in Dutch patients with phenylketonuria. The National PKU Steering Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Growth in patients with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Physical growth in patients with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Does impaired growth of PKU patients correlate with the strictness of dietary treatment? National Dutch PKU Steering Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Physical growth of children treated for phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Nutrient intake and growth of infants with phenylketonuria undergoing therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Evaluation of nutritional status and pathophysiology of growth retardation in patients with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Growth and body composition in children with classical phenylketonuria: results in 34 patients and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

The intake of total protein, natural protein and protein substitute and growth of height and head circumference in Dutch infants with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Protein insufficiency and linear growth restriction in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

The use of prealbumin concentration as a biomarker of nutritional status in treated phenylketonuric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Comparison of the Prevalence of Shortness, Underweight, and Overweight among US Children Aged 0 to 59 Months by Using the CDC 2000 and the WHO 2006 Growth Charts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Development of a WHO growth reference for school-aged children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Measuring body composition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Variation in childhood and adolescent obesity prevalence defined by international and country-specific criteria in England and the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Accuracy of simple clinical and epidemiological definitions of childhood obesity: systematic review and evidence appraisal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

What is the best way to measure waist circumference?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Waist circumference correlates with metabolic syndrome indicators better than percentage fat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Waist circumference: a simple, inexpensive, and reliable tool that should be included as part of physical examinations in the doctor's office

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Body mass index, waist circumference, and clustering of cardiovascular disease risk factors in a biracial sample of children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Persistence of pre-diabetes in overweight and obese Hispanic children: association with progressive insulin resistance, poor beta-cell function, and increasing visceral fat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Are age references for waist circumference, hip circumference and waist-hip ratio in Dutch children useful in clinical practice?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Is body composition important for paediatricians?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

How well do waist circumference and body mass index reflect body composition in pre-pubertal children?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Ethnic group differences in waist circumference percentiles among U.S. children and adolescents: estimates from the 1999-2008 National Health and Nutrition Examination Surveys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Waist circumference percentiles for Canadian youth 11-18y of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

The development of waist circumference percentiles in British children aged 5.0-16.9 y

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Waist circumference percentiles for 7- to 15-year-old Australian children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

The metabolic syndrome in children and adolescents - an IDF consensus report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Bioelectrical impedance analysis--part I: review of principles and methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Bioelectrical impedance analysis-part II: utilization in clinical practice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Body composition determination by bioimpedance: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Excess weight among children with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Nutrient intakes and physical growth of children with phenylketonuria undergoing nutrition therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Whole body composition analysis by the BodPod air-displacement plethysmography method in children with phenylketonuria shows a higher body fat percentage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Early macronutrient intake and overweight at five years of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Relationship between growth and feeding in infancy and body mass index at the age of 6 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Metabolic programming: Role of nutrition in the immediate postnatal life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Peak bone mass in patients with phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Bone impairment in phenylketonuria is characterized by circulating osteoclast precursors and activated T cell increase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Increased spontaneous osteoclastogenesis from peripheral blood mononuclear cells in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Vitamin B12 deficiency in adolescents and young adults with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Vitamin B12 and vitamin B6 supplementation is needed among adults with phenylketonuria (PKU)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Increased risk of vitamin B12 deficiency in patients with phenylketonuria on an unrestricted or relaxed diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Vitamin B12 deficiency in adolescents and young adults with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Vitamin B12 deficiency in an adult phenylketonuric patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Serum vitamin B12 concentrations within reference values do not exclude functional vitamin B12 deficiency in PKU patients of various ages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Folate intake and the risk of colorectal cancer: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Vitamin B-6 status of school-aged patients with phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Effect of diet on plasma total antioxidant status in phenylketonuric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Plasma zinc, copper, and erythrocyte superoxide dismutase in children with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Zinc and copper status of treated children with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Poor zinc and selenium status in phenylketonuric children and adolescents in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Zinc-induced copper deficiency in Wilson disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Antioxidant status in hyperphenylalaninemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Evidence that l-Carnitine and Selenium Supplementation Reduces Oxidative Stress in Phenylketonuric Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Serum-selenium concentrations in patients with maple-syrup-urine disease and phenylketonuria under dieto-therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Serum selenium levels in individuals on PKU diets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Clinical and nutritional evaluation of phenylketonuric patients on tetrahydrobiopterin monotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Plasma micronutrient concentrations in infants undergoing therapy for phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Iron status and iron supplementation in children with classical phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Low iron stores in infants and children with treated phenylketonuria: a population at risk for iron-deficiency anaemia and associated cognitive deficits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

Iron status of children with phenylketonuria undergoing nutrition therapy assessed by transferrin receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.023

10.1016/J.YMGME.2011.08.023

7 January 2021

Identifiers

DOI

1 reference

25 August 2017

1 reference